A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma

Table 3 The diagnostic value of immunodiagnostic model

Group	AUC (95%CI)	Sen (%)	Spe (%)	Accuracy	YI	PPV (%)	NPV (%)	P
PDAC vs. NC								0.62
Test	0.80(0.75–0.86)	58.00	86.00	72.00	0.44	80.56	67.19
Validation	0.78(0.70–0.86)	58.60	87.14	71.43	0.43	81.25	66.30
PDAC vs. BPD								0.50
Test	0.80(0.73–0.86)	58.00	86.25	70.56	0.43	79.45	66.92
Validation	0.83(0.76–0.90)	55.71	100.00	75.59	0.56	100.00	64.77
CA19-9 status vs. NC								0.06
CA19-9(+)	0.78(0.72–0.84)	55.45	85.29	74.17	0.41	69.14	76.31
CA19-9(-)	0.86(0.80–0.93)	65.38	85.29	82.65	0.51	40.48	94.16
Early vs. Advanced								0.23
Early	0.77(0.70–0.84)	54.10	85.29	77.06	0.39	56.90	83.82
Advanced	0.82(0.77–0.88)	61.11	85.29	76.92	0.46	68.75	80.56

AUC: area under curve, 95%CI: 95% confidence interval, Sen: sensitivity, Spe: specificity, YI: Youden’s index, PPV: positive predictive value, NPV: negative predictive value, PDAC: pancreatic ductal adenocarcinoma, NC: normal control, BPD: benign pancreatic diseases, P: Delong test results between two AUCs.

ISSN: 1475-2867